Albumin Slowdown in China Forces Grifols Downgrade: Morgan Stanley Moves to Equal Weight
Morgan Stanley downgraded Grifols stock to Equal Weight with a lower €11 price target, citing slowdowns in key products like albumin in China and alpha-1.
/ 894 items
#Healthcare↓
Vertex's Povetacicept Delivers Solid IgAN Data — But No Real Threat to Vera's Atacicept, Says BofA
BofA reaffirms Buy on Vera Therapeutics; Vertex’s povetacicept Phase 3 interim results in IgAN meet expectations but pose no major competitive threat.
FDA Issues Warning Letter to Novo Nordisk Over Delayed Safety Reports for Ozempic and Victoza
Novo Nordisk receives FDA warning letter after 2025 Plainsboro inspection revealed failures in timely reporting serious side effects for drugs like Ozempic and Victoza. Company says no impact on production.
FDA Lifts Rejection and Schedules August 2026 Review for Deramiocel
Capricor Therapeutics receives new PDUFA target date of August 22, 2026 for Deramiocel BLA. Potential first therapy to treat both heart and skeletal muscle damage in Duchenne muscular dystrophy (DMD).
BioNTech Co-Founders Ugur Sahin and Özlem Türeci Launch New mRNA Biotech as Company Sharpens Focus on Cancer Pipeline
BioNTech co-founders Ugur Sahin & Özlem Türeci are starting an independent next-gen mRNA company by end-2026. BioNTech keeps focus on oncology (15 Phase 3 trials).
BridgeBio Stock Gets Double Upgrade: Analysts See $93–$94 Target Ahead
JPMorgan & William Blair raise BridgeBio price targets to $93–$94 on strong Attruby launch and achondroplasia data.